Founder, Perlstein Lab, PBC
Over the course of the last decade, first as a graduate student at Harvard and then as an independent postdoctoral fellow at Princeton, Dr. Ethan Perlstein developed an approach to studying complex drugs in simple model organisms called evolutionary pharmacology.
Last year Dr. Perlstein left academia in the face of “postdocalypse,” declared scientific independence, and decided to apply evolutionary pharmacology to orphan/rare diseases.
His journey of professional reinvention includes forays into tweeting, blogging, and crowdfunding. It culminates in Perlstein Lab, PBC, a San Francisco-based biotech startup and public benefit corporation that is focused on precision orphan disease drug discovery.